Biomarkers & Diagnostics for Precision Medicine Development in Complex & Rare Diseases
The inaugural Biomarkers & Diagnostics for Complex & Rare Diseases Summit will unite leading pharma, biotech, academic and healthcare organizations to advance the application of precision medicine across a range of diseases, including examples from; Neurology, Cardiovascular, Renal, Metabolic, Dermatology, NASH and rare diseases.
Tackling the discovery, translation, development and commercialization of biomarker-driven and Dx-enabled therapeutics, this meeting will draw on the transferable learnings from a multitude of disease areas to improve treatment management and decision making and push the boundaries of the standard of care for patients.
Join the conversation this June to bring patients of complex and rare diseases closer to efficacious, clinically available precision medicines.
Assistant Vice President, Personalized Health
Inova Health System
Chief Scientific Officer
Chief Scientific Officer & Vice President, Neurodegeneration Research
Eli Lilly & Co.
Executive Director, Clinical Evaluation, Innovation & Policy, Officer of Clinical Affairs
Blue Cross Blue Shield Association
Past BDx Summit Attendees Have Said:
“Very much liked the size of the conference, the ability and time given to interact with other participants was much appreciated. From a personal note, I appreciated the Hanson Wade staff friendliness and genuine desire to help the Speakers and ensure the best experience for the attendees.”
Head, Clinical Trial Biosample Management, Merck KGaA
“Interesting, fast paced well organised. Very good meeting.”
Strategic Account Manager, AbbVie
“Vibrant collaboration opportunities.”
Clinical Senior Lecturer, Imperial College
“Good program, interested speakers, valuable discussion.”
Associate Regulatory Affairs Director, Astellas
“Educational, friendly, worthwhile.”
Translational Sciences Team Leader, GSK